<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">PMJ</journal-id>
<journal-id journal-id-type="hwp">sppmj</journal-id>
<journal-id journal-id-type="nlm-ta">Palliat Med</journal-id>
<journal-title>Palliative Medicine</journal-title>
<issn pub-type="ppub">0269-2163</issn>
<issn pub-type="epub">1477-030X</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0269216311428528</article-id>
<article-id pub-id-type="publisher-id">10.1177_0269216311428528</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The role of paracetamol and nonsteroidal anti-inflammatory drugs in addition to WHO Step III opioids in the control of pain in advanced cancer. A systematic review of the literature</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Nabal</surname><given-names>Maria</given-names></name>
</contrib>
<aff id="aff1-0269216311428528">Palliative Care Supportive Team, Hospital Universitario Arnau de Vilanova Lleida, Spain</aff>
</contrib-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Librada</surname><given-names>Silvia</given-names></name>
</contrib>
<aff id="aff2-0269216311428528">Enterprising Solutions for Health, S.L. Badajoz, Spain</aff>
</contrib-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Redondo</surname><given-names>Maria Josè</given-names></name>
</contrib>
<aff id="aff3-0269216311428528">Palliative Care Supportive Team, Badajoz Regional Palliative Care Program of Extremadura, Spain</aff>
</contrib-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Pigni</surname><given-names>Alessandra</given-names></name>
</contrib>
<aff id="aff4-0269216311428528">Palliative Care, Pain Therapy and Rehabilitation Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy</aff>
</contrib-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Brunelli</surname><given-names>Cinzia</given-names></name>
</contrib>
<aff id="aff5-0269216311428528">Palliative Care, Pain Therapy and Rehabilitation Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy</aff>
</contrib-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Caraceni</surname><given-names>Augusto</given-names></name>
</contrib>
<aff id="aff6-0269216311428528">Palliative Care, Pain Therapy and Rehabilitation Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-0269216311428528">Professor Augusto Caraceni, Palliative Care, Pain Therapy and Rehabilitation, Fondazione IRCCS Istituto Nazionale dei Tumori, European Palliative Care Research Centre (PRC), Norwegian University of Science and Technology, via Venezian 1, 20133 Milano, Italy. Email: <email>augusto.caraceni@istitutotumori.mi.it</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2012</year>
</pub-date>
<volume>26</volume>
<issue>4</issue>
<fpage>305</fpage>
<lpage>312</lpage>
<permissions>
<copyright-statement>© The Author(s) 2011</copyright-statement>
<copyright-year>2011</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p><bold>Background:</bold> Nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol are used widely in the management of mild to moderate cancer pain and are frequently combined with opioids in the treatment of moderate to severe pain.</p>
<p><bold>Aim:</bold> To perform a systematic literature review of the evidence of the efficacy and toxicity of NSAIDs or paracetamol added to WHO Step III opioid treatment for cancer pain.</p>
<p><bold>Design and data sources:</bold> A systematic literature review of MedLine, EMBASE and Cochrane Central register of controlled trials database was carried out using both text words and MeSH/EMTREE terms.</p>
<p><bold>Results:</bold> Seven eligible papers were retrieved from the new search and five from the Cochrane review. Five of seven studies showed an additive effect of NSAIDs when combined with opioids either by improving analgesia (three studies) or by reducing the opioid dose (two studies). Paracetamol was only marginally effective in one of five trials. The study designs were not adequate to assess differences in side effects between the opioids alone and opioids in combination with NSAIDs or paracetamol.</p>
<p><bold>Conclusions:</bold> The evidence from the available clinical trials is of limited amount and quality, but it weakly supports the proposal that the addition of an NSAIDs to WHO Step III opioids can improve analgesia or reduce opioid dose requirement. There is insufficient evidence to support the use of paracetamol in combination with Step III opioids. Data on the toxicity of NSAIDs in this indication are insufficient owing to the small number of patients and the short duration of treatment reported in the studies.</p>
</abstract>
<kwd-group>
<kwd>neoplasm</kwd>
<kwd>NSAIDs</kwd>
<kwd>opioids</kwd>
<kwd>pain</kwd>
<kwd>paracetamol</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sectiontion1-0269216311428528" sec-type="intro">
<title>Introduction</title>
<p>The World Health Organization (WHO) method for cancer pain management<sup><xref ref-type="bibr" rid="bibr1-0269216311428528">1</xref></sup> has been helpful in improving the control of pain in a very significant percentage of cases, as shown by a systematic literature review.<sup><xref ref-type="bibr" rid="bibr2-0269216311428528">2</xref></sup> The method is usually summarized by the WHO analgesic ladder in which the choice of analgesics is determined by the severity of the pain. Step I, for mild pain, recommends the use of paracetamol and/or nonsteroidal anti-inflammatory drugs (NSAIDs). The same drugs are proposed also at Step II and Step III of the ladder in addition to opioids.</p>
<p>The use of NSAIDs has advantages, such as universal availability, affordability (in several cases), familiarity among patients and their families, and effectiveness against pain arising from various aetiologies. However, the use of NSAIDs is not without problems: NSAIDs have a ceiling effect, are associated with the risks of gastrointestinal bleeding, and are relatively contraindicated in patients with renal, hepatic and cardiac failure.<sup><xref ref-type="bibr" rid="bibr3-0269216311428528">3</xref></sup> Paracetamol is considered a mild analgesic, is devoid of relevant side effects within a given range of dosages, and has been suggested as an alternative to NSAIDs in the same indications.<sup><xref ref-type="bibr" rid="bibr1-0269216311428528">1</xref></sup></p>
<p>A Cochrane Collaboration review specifically dedicated to evaluate the role of NSAIDs and paracetamol in the treatment of cancer pain<sup><xref ref-type="bibr" rid="bibr4-0269216311428528">4</xref></sup> concluded that NSAIDs and paracetamol are more effective than placebo for cancer pain and that there is no clear evidence to support the superior safety or efficacy of one NSAIDs over another in this indication. When NSAIDs or paracetamol were combined with opioids and their clinical effects compared with those of opioids alone, five out of six studies demonstrated superiority of the combination treatment.<sup><xref ref-type="bibr" rid="bibr4-0269216311428528">4</xref></sup> The 2001 recommendations of the European Association of Palliative Care (EAPC)<sup><xref ref-type="bibr" rid="bibr5-0269216311428528">5</xref></sup> on the use of morphine and other opioids for chronic cancer pain management did not consider the role of paracetamol and NSAIDs. In the revision and update of the EAPC recommendations, promoted by the European Palliative Care Research Collaborative,<sup><xref ref-type="bibr" rid="bibr6-0269216311428528">6</xref></sup> a literature review of existing guidelines and experts’ opinions<sup><xref ref-type="bibr" rid="bibr7-0269216311428528">7</xref></sup> suggested that one relevant topic in the guidelines revision had to be the role of NSAIDs and paracetamol when used in addition to Step III opioids.</p>
<p>The present article therefore presents a systematic literature review of the evidence of the efficacy and toxicity of NSAIDs or paracetamol added to Step III opioid treatment for moderate to severe cancer pain when compared to opioids alone.<sup><xref ref-type="bibr" rid="bibr4-0269216311428528">4</xref></sup></p>
</sec>
<sec id="sectiontion2-0269216311428528" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="sectiontion3-0269216311428528">
<title>Identification and selection of studies</title>
<p>The literature search was conducted on MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials databases. The search strategy for MEDLINE, which used both text words and MeSH/EMTREE terms, is shown in <xref ref-type="table" rid="table1-0269216311428528">Table 1</xref>, and appropriately revised strategies were developed for each database. A hand-search of the reference lists of identified papers was also performed. The Cochrane review was updated to November 2004 and the search strategy limits were set in March 2003. We decided to set our search strategy limits in order not to miss any article published since at least 2003. In the same review, although the title specifically refers to paracetamol, the searches on the various databases did not explicitly address the keywords ‘paracetamol’ or ‘acetaminophen’. Therefore another search was carried out to retrieve potentially missing papers on the use of paracetamol published before 2003. Inclusion criteria for relevant study selection were: conducted in human, adult patients with chronic cancer pain; a randomized controlled trial (RCT) or a meta-analysis of reported data from RCTs; studies containing data on patient-reported efficacy and/or side effects of NSAIDs or paracetamol in addition to opioids compared to placebo or opioids alone; and written in English. Abstracts identified through the search were separately screened for eligibility by the authors; potentially eligible studies’ full-text papers were examined. Disagreements among reviewers were resolved by discussion, and reasons for excluding trials were reported.</p>
<table-wrap id="table1-0269216311428528" position="float">
<label>Table 1.</label>
<caption><p>Medline search strategy.</p></caption>
<graphic alternate-form-of="table1-0269216311428528" xlink:href="10.1177_0269216311428528-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
</colgroup>
<tbody>
<tr>
<td>5</td>
<td>#1 OR #4</td>
</tr>
<tr>
<td>4</td>
<td>#2 NOT #3</td>
</tr>
<tr>
<td/>
<td>Limits: English, Publication Date from 2002 to 2010</td>
</tr>
<tr>
<td>3</td>
<td>NSAID AND neoplasm AND pain</td>
</tr>
<tr>
<td/>
<td>Limits: Animals, Publication Date from 2002 to 2010</td>
</tr>
<tr>
<td>2</td>
<td>NSAID AND neoplasm AND pain</td>
</tr>
<tr>
<td/>
<td>Limits: English, Publication Date from 2002 to 2010</td>
</tr>
<tr>
<td>1</td>
<td>acetaminophen OR paracetamol AND neoplasm AND pain</td>
</tr>
<tr>
<td/>
<td>Limits: English</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>In addition to the newly retrieved papers, all the studies included in the available Cochrane review<sup><xref ref-type="bibr" rid="bibr4-0269216311428528">4</xref></sup> were evaluated for eligibility in the present analysis.</p>
</sec>
<sec id="sectiontion4-0269216311428528">
<title>Study quality and content description</title>
<p>In accordance with the guidance from the Cochrane Handbook for Systematic Reviews of Interventions (<ext-link ext-link-type="uri" xlink:href="http://www.cochrane.org/resources/handbook">www.cochrane.org/resources/handbook</ext-link>), content and quality of each study were summarized as:</p>
<list id="list1-0269216311428528" list-type="bullet">
<list-item><p>study design (meta-analysis or randomized controlled trial);</p></list-item>
<list-item><p>comparators: drugs compared in the trial;</p></list-item>
<list-item><p>sample size and drop-out rate;</p></list-item>
<list-item><p>previous opioid therapy;</p></list-item>
<list-item><p>study limitations (lack of allocation concealment, lack of blinding, large losses to follow-up, failure to adhere to an intention to treat analysis, stopping early for patient benefit or failure to report outcomes, typically those for which no effect was observed);</p></list-item>
<list-item><p>efficacy and side effects and reported outcomes.</p></list-item>
</list>
</sec>
</sec>
<sec id="sectiontion5-0269216311428528" sec-type="results">
<title>Results</title>
<p>The literature search retrieved 803 papers (<xref ref-type="fig" rid="fig1-0269216311428528">Figure 1</xref>). All abstracts were read by the authors and 12 papers were selected for full-text examination.<sup><xref ref-type="bibr" rid="bibr8-0269216311428528">8</xref>–<xref ref-type="bibr" rid="bibr19-0269216311428528">19</xref></sup></p>
<fig id="fig1-0269216311428528" position="float">
<label>Figure 1.</label>
<caption><p>Flow diagram.</p></caption>
<graphic xlink:href="10.1177_0269216311428528-fig1.tif"/>
</fig>
<p>Four papers were excluded because the addition of paracetamol to an opioid was compared to a different opioid,<sup><xref ref-type="bibr" rid="bibr16-0269216311428528">16</xref>–<xref ref-type="bibr" rid="bibr19-0269216311428528">19</xref></sup> which made it impossible to evaluate the role of paracetamol per se. One paper<sup><xref ref-type="bibr" rid="bibr9-0269216311428528">9</xref></sup> was excluded because it compared a cobrotoxin-containing analgesic compound to tramadol. Therefore, the new eligible studies were seven in number.<sup><xref ref-type="bibr" rid="bibr8-0269216311428528">8</xref>,<xref ref-type="bibr" rid="bibr10-0269216311428528">10</xref>–<xref ref-type="bibr" rid="bibr15-0269216311428528">15</xref></sup></p>
<p>When the Cochrane review search was repeated for the period preceding 2003, including paracetamol and acetaminophen as keywords, no additional records could be identified.</p>
<p>Six studies already included in the Cochrane review contained efficacy / side effects data on NSAIDs or paracetamol in addition to Step III opioids<sup><xref ref-type="bibr" rid="bibr20-0269216311428528">20</xref>-<xref ref-type="bibr" rid="bibr25-0269216311428528">25</xref></sup>; one study<sup><xref ref-type="bibr" rid="bibr21-0269216311428528">21</xref></sup> was excluded because the objective was to establish the equianalgesic dose between codeine every 12 hours and codeine every 6 hours, and because codeine doses varied in the comparison groups making it impossible to estimate the analgesic contribution of paracetamol. Five studies from the Cochrane review were eligible for the analysis.</p>
<p>The present review is thus based on 12 studies. Seven studies compared NSAIDs/opioid combinations with opioid alone<sup><xref ref-type="bibr" rid="bibr8-0269216311428528">8</xref>,<xref ref-type="bibr" rid="bibr10-0269216311428528">10</xref>,<xref ref-type="bibr" rid="bibr20-0269216311428528">20</xref>,<xref ref-type="bibr" rid="bibr22-0269216311428528">22</xref>–<xref ref-type="bibr" rid="bibr25-0269216311428528">25</xref></sup> (<xref ref-type="table" rid="table2-0269216311428528">Table 2</xref>) and five investigated paracetamol/opioid combinations<sup><xref ref-type="bibr" rid="bibr11-0269216311428528">11</xref>–<xref ref-type="bibr" rid="bibr15-0269216311428528">15</xref></sup> (<xref ref-type="table" rid="table3-0269216311428528">Table 3</xref>).</p>
<table-wrap id="table2-0269216311428528" position="float">
<label>Table 2.</label>
<caption><p>Studies on the combination of nonsteroidal antinflammatory drugs (NSAIDs) with opioids in comparison to treatment with opioids alone.</p></caption>
<graphic alternate-form-of="table2-0269216311428528" xlink:href="10.1177_0269216311428528-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left" rowspan="2">Ref</th>
<th align="left" rowspan="2">AUTHOR/ YEAR</th>
<th align="left" rowspan="2">STUDY DESIGN (sample size)</th>
<th align="left" rowspan="2">DRUGS COMPARED</th>
<th align="left" rowspan="2">STUDY DURATION (days)</th>
<th align="left" rowspan="2">PREVIOUS OPIOID THERAPY</th>
<th align="left" colspan="3">REPORTED OUTCOMES</th>
</tr>
<tr>
<th align="left">EFFICACY Pain relief</th>
<th align="left">SIDE EFFECTS</th>
<th align="left">OPIOID CONSUMPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>8</td>
<td><bold>Duarte-Souza 2007</bold></td>
<td>Double-blind crossover 34</td>
<td>DIP + MO vs MO</td>
<td>4</td>
<td>II</td>
<td>&gt; DIP + MO</td>
<td>NED</td>
<td>NA</td>
</tr>
<tr>
<td>10</td>
<td><bold>Mercadante 2002</bold></td>
<td>Open parallel 50</td>
<td>K + MO vs MO</td>
<td>Till death range 21–39</td>
<td>III</td>
<td>NED</td>
<td>&gt; Constipation in MO &gt; Gastric discomfort in K + MO</td>
<td>&lt; opioid escalation index in K + MO</td>
</tr>
<tr>
<td>23</td>
<td><bold>Johnson 1994</bold></td>
<td>Double-blind crossover 26</td>
<td>CMT + MO vs MO</td>
<td>3</td>
<td>III</td>
<td>NED</td>
<td>NED</td>
<td>NA</td>
</tr>
<tr>
<td>20</td>
<td><bold>Bjorkman 1993</bold></td>
<td>Double-blind crossover 16</td>
<td>DIC + MO i.v. vs MO i.v.</td>
<td>5</td>
<td>III</td>
<td>NED</td>
<td>NED</td>
<td>&lt; opioid daily dose in DIC + MO</td>
</tr>
<tr>
<td>24</td>
<td><bold>Lomen 1986</bold></td>
<td>Double-blind crossover 26</td>
<td>FLU + var. opioids vs var. opioids</td>
<td>42</td>
<td>III</td>
<td>NED</td>
<td>NED</td>
<td>NR</td>
</tr>
<tr>
<td>25</td>
<td><bold>Weingart 1985</bold></td>
<td>Double-blind crossover 14</td>
<td>IBU + var. opioids vs var. opioids</td>
<td>9</td>
<td>III</td>
<td>&gt; IBU + var.</td>
<td>NED</td>
<td>NR</td>
</tr>
<tr>
<td>22</td>
<td><bold>Ferrer Brechner 1984</bold></td>
<td>Double-blind 4 days crossover 30</td>
<td>IBU + ME vs ME</td>
<td>4 h</td>
<td>III</td>
<td>&gt;IBU + ME</td>
<td>NED</td>
<td>NA</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0269216311428528">
<p>i.v., intravenous; var., various.</p></fn>
<fn id="table-fn2-0269216311428528">
<p><bold>Key</bold>: DIP = dipyrone; DIC = diclofenac; IBU = ibuprofen; K = ketorolac; FLU = flurbiprofen; CMT = choline magnesium trisalicylate; P = paracetamol; MO = morphine; ME = methadone; HY = hydromorphone; NED = no evidence of difference; NR = not reported; BTP = breakthrough pain; NA = not applicable (opioid dose is kept unchanged by design).</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table3-0269216311428528" position="float">
<label>Table 3.</label>
<caption><p>Studies on the addition of paracetamol to opioids in comparison to treatment with opioids alone.</p></caption>
<graphic alternate-form-of="table3-0269216311428528" xlink:href="10.1177_0269216311428528-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left" rowspan="2">Ref</th>
<th align="left" rowspan="2">AUTHOR/YEAR</th>
<th align="left" rowspan="2">STUDY DESIGN (sample size)</th>
<th align="left" rowspan="2">DRUGS COMPARED</th>
<th align="left" rowspan="2">STUDY DURATION (days)</th>
<th align="left" rowspan="2">PREVIOUS OPIOID THERAPY</th>
<th align="left" colspan="3">REPORTED OUTCOMES</th>
</tr>
<tr>
<th align="left">EFFICACY Pain relief</th>
<th align="left">SIDE EFFECTS</th>
<th align="left">OPIOID CONSUMPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>11</td>
<td><bold>Israel 2010</bold></td>
<td>Double-blind crossover 31</td>
<td>P + var. opioids vs var. opioids</td>
<td>5</td>
<td>III</td>
<td>NED</td>
<td>NED</td>
<td>NR NED in the no. of BTP medications</td>
</tr>
<tr>
<td>12</td>
<td><bold>Cubero 2010</bold></td>
<td>Double-blind 50</td>
<td>P + ME vs ME</td>
<td>7</td>
<td>III Switch from MO</td>
<td>NED</td>
<td>&gt; somnolence ME + P</td>
<td>NR</td>
</tr>
<tr>
<td>13</td>
<td><bold>Tasmacioglu 2009</bold></td>
<td>Double blind 43</td>
<td>P + i.v. MO (PCA) vs i.v. MO (PCA)</td>
<td>1</td>
<td>II</td>
<td>NED</td>
<td>NED</td>
<td>NED</td>
</tr>
<tr>
<td>14</td>
<td><bold>Stockler 2004</bold></td>
<td>Double blind crossover 34</td>
<td>P + MO or HY vs MO or HY</td>
<td>4</td>
<td>III</td>
<td>&gt; P</td>
<td>NED</td>
<td>NR NED in the no. of BTP medications</td>
</tr>
<tr>
<td>15</td>
<td><bold>Axelsson 2003</bold></td>
<td>Double blind crossover 42</td>
<td>P + MO vs MO</td>
<td>14</td>
<td>III</td>
<td>NED</td>
<td>NR</td>
<td>NR</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0269216311428528">
<p>i.v., intravenous; var., various.</p></fn>
<fn id="table-fn4-0269216311428528">
<p>Key: P = paracetamol; MO = morphine; ME = methadone; HY = hydromorphone; NED = no evidence of difference; NR = not reported; BTP = breakthrough pain; PCA = patient-controlled analgesia.</p></fn>
</table-wrap-foot>
</table-wrap>
<sec id="sectiontion6-0269216311428528">
<title>NSAIDs in addition to opioids</title>
<p>Five of seven studies showed a positive impact of the NSAIDs addition to opioids; three demonstrated improved analgesia<sup><xref ref-type="bibr" rid="bibr8-0269216311428528">8</xref>,<xref ref-type="bibr" rid="bibr22-0269216311428528">22</xref>,<xref ref-type="bibr" rid="bibr25-0269216311428528">25</xref></sup> and two a reduction of opioid consumption.<sup><xref ref-type="bibr" rid="bibr10-0269216311428528">10</xref>,<xref ref-type="bibr" rid="bibr20-0269216311428528">20</xref></sup></p>
<p>In Duarte Souza’s study,<sup><xref ref-type="bibr" rid="bibr8-0269216311428528">8</xref></sup> morphine was compared with a combination of morphine and dipyrone in 34 WHO Step III opioid-naïve patients, in a crossover placebo-controlled study design of 48 hours duration for each phase. The dose of morphine was kept constant at 10 mg every 4 hours. Average pain intensity at baseline was between 6.8 and 7.3 on a 0 to 10 numerical rating scale (0–10 NRS), respectively for the two groups. Although the results showed an additive analgesic effect of dypirone, a potential bias due to a carryover effect was not accounted for in the study design or in the analysis.</p>
<p>In two studies<sup><xref ref-type="bibr" rid="bibr22-0269216311428528">22</xref>,<xref ref-type="bibr" rid="bibr25-0269216311428528">25</xref></sup> the addition of ibuprofen (respectively 600 and 1600 mg/day) improved pain relief. The study by Ferrer-Brechner<sup><xref ref-type="bibr" rid="bibr22-0269216311428528">22</xref></sup> evaluated the addition of ibuprofen 600 mg to methadone (2.5 or 5 mg) in patients with a moderate to severe baseline pain, over a 4 h observation period after a single dose administration. More than 50% of patients were concurrently treated with Step III opioids.</p>
<p>In the study by Weingart<sup><xref ref-type="bibr" rid="bibr25-0269216311428528">25</xref></sup> mean baseline pain intensity was 44 mm (0–100 mm visual analogue scale [VAS]) and the average parenteral morphine total daily equivalent dose was 31 mg. Ibuprofen was given orally 400 mg q.i.d.</p>
<p>In the study by Mercadante,<sup><xref ref-type="bibr" rid="bibr10-0269216311428528">10</xref></sup> ketorolac (60 mg/day orally) in addition to morphine was compared to morphine alone in 50 patients. Patients were included if baseline pain intensity was less than 4 (0–10 NRS). No difference in analgesic efficacy in the first three weeks was demonstrated, but there was a reduction in morphine consumption with the addition of ketorolac. Similar results were found in another study<sup><xref ref-type="bibr" rid="bibr20-0269216311428528">20</xref></sup> when diclofenac (100 mg/day rectal administration) was added to morphine; in this study, morphine dose (median daily oral morphine dose = 105 mg) was titrated to effect by intravenous patient-controlled analgesia infusions before adding diclofenac or placebo. Baseline pain intensity was 36 mm (VAS). Average pain reduction was 26% (not statistically significant) while morphine requirements were significantly reduced from a mean daily dose of 95 mg to 83 mg. In three studies,<sup><xref ref-type="bibr" rid="bibr8-0269216311428528">8</xref>,<xref ref-type="bibr" rid="bibr22-0269216311428528">22</xref>,<xref ref-type="bibr" rid="bibr23-0269216311428528">23</xref></sup> the opioid dose was kept unchanged from baseline by design, whereas two papers did not report on this issue.<sup><xref ref-type="bibr" rid="bibr24-0269216311428528">24</xref>,<xref ref-type="bibr" rid="bibr25-0269216311428528">25</xref></sup></p>
<p>Two studies did not show differences between the intervention and the control arm.<sup><xref ref-type="bibr" rid="bibr23-0269216311428528">23</xref>,<xref ref-type="bibr" rid="bibr24-0269216311428528">24</xref></sup> In one of them,<sup><xref ref-type="bibr" rid="bibr23-0269216311428528">23</xref></sup> a single daily dose of choline magnesium trisalicylate (1500 mg) was compared, in a three-day cross over design with placebo, in a group of patients with pain due to bony metastatic lesions already treated with opioids. Pain intensity was equal to 23 mm on a 100 mm VAS in the intervention group and to 17 mm in the placebo group. Oral morphine dose was kept stable during the study ranging from 20 to 100 mg/day. The other study<sup><xref ref-type="bibr" rid="bibr24-0269216311428528">24</xref></sup> added flurbiprofen to a number of different opioids. Baseline morning pain was 2.4 (0 = no pain, 4 = extreme pain), noon pain 2.3 and night pain 2.2. An improvement in pain score did not reach statistical significance, while the Karnofsky performance scale improved in the flurbiprofen phase of the study, but this change was found only in one of the investigator’s group of patients. As regards side effects, six studies failed to demonstrate any statistically significant difference between the administration of the opioid alone and the NSAIDs combination, and only one showed some differences.<sup><xref ref-type="bibr" rid="bibr10-0269216311428528">10</xref></sup> Constipation was more frequent in the morphine group (<italic>p</italic> = 0.006), whereas gastric discomfort was more frequent in patients treated with ketorolac (<italic>p</italic> &lt; 0.0005).</p>
</sec>
<sec id="sectiontion7-0269216311428528">
<title>Paracetamol in addition to opioids</title>
<p>Five randomized controlled trials,<sup><xref ref-type="bibr" rid="bibr11-0269216311428528">11</xref>–<xref ref-type="bibr" rid="bibr15-0269216311428528">15</xref></sup> enrolling in total 200 patients, were double-blind comparisons of opioid plus paracetamol versus opioid alone, and three of them used a crossover design<sup><xref ref-type="bibr" rid="bibr11-0269216311428528">11</xref>,<xref ref-type="bibr" rid="bibr14-0269216311428528">14</xref>,<xref ref-type="bibr" rid="bibr15-0269216311428528">15</xref></sup> (<xref ref-type="table" rid="table3-0269216311428528">Table 3</xref>). Patients received different opioids in different studies: morphine,<sup><xref ref-type="bibr" rid="bibr13-0269216311428528">13</xref>,<xref ref-type="bibr" rid="bibr15-0269216311428528">15</xref></sup> methadone,<sup><xref ref-type="bibr" rid="bibr12-0269216311428528">12</xref></sup> morphine or hydromorphone,<sup><xref ref-type="bibr" rid="bibr14-0269216311428528">14</xref></sup> and miscellaneous opioids.<sup><xref ref-type="bibr" rid="bibr11-0269216311428528">11</xref></sup> Daily doses of paracetamol ranged from 3 to 5 g. The dose of opioid was variable and it was stabilized to obtain low to moderate pain ranging from 2 to 4 on a 0 to 10 numerical scale in most studies,<sup><xref ref-type="bibr" rid="bibr10-0269216311428528">10</xref>–<xref ref-type="bibr" rid="bibr12-0269216311428528">12</xref>,<xref ref-type="bibr" rid="bibr14-0269216311428528">14</xref></sup> while it was severe (7 over 10) in only one study using patient controlled analgesia (PCA) with morphine infusion as baseline opioid and comparator.<sup><xref ref-type="bibr" rid="bibr13-0269216311428528">13</xref></sup></p>
<p>Four studies<sup><xref ref-type="bibr" rid="bibr11-0269216311428528">11</xref>–<xref ref-type="bibr" rid="bibr13-0269216311428528">13</xref>,<xref ref-type="bibr" rid="bibr15-0269216311428528">15</xref></sup> failed to confirm any benefit of add-on paracetamol treatment, whereas Stockler<sup><xref ref-type="bibr" rid="bibr14-0269216311428528">14</xref></sup> reported a slight mean difference of 0.4, on a 0–10 NRS, in favour of the paracetamol combination. It is noteworthy that this study used the highest paracetamol dose (5 g/day) but had a short follow-up (only 96 h).</p>
<p>Four papers<sup><xref ref-type="bibr" rid="bibr11-0269216311428528">11</xref>,<xref ref-type="bibr" rid="bibr12-0269216311428528">12</xref>,<xref ref-type="bibr" rid="bibr14-0269216311428528">14</xref>,<xref ref-type="bibr" rid="bibr15-0269216311428528">15</xref></sup> did not report data regarding the effect on opioid consumption, and one study<sup><xref ref-type="bibr" rid="bibr13-0269216311428528">13</xref></sup> found no evidence of differences. Two studies<sup><xref ref-type="bibr" rid="bibr11-0269216311428528">11</xref>,<xref ref-type="bibr" rid="bibr14-0269216311428528">14</xref></sup> failed to show any difference also in the number of medications required for breakthrough pain management.</p>
<p>Side effects were similar in the patient groups analysed except for one,<sup><xref ref-type="bibr" rid="bibr12-0269216311428528">12</xref></sup> in which more somnolence was present in patients on methadone plus paracetamol.</p>
</sec>
<sec id="sectiontion8-0269216311428528">
<title>Quality of evidence</title>
<p>The quality of studies retrieved is summarized in <xref ref-type="table" rid="table4-0269216311428528">Table 4</xref>. Most studies were carried out on a small number of patients (<xref ref-type="table" rid="table2-0269216311428528">Tables 2</xref> and <xref ref-type="table" rid="table3-0269216311428528">3</xref>), and sample size calculations were not reported by several. Some studies had large losses to follow-up (&gt;20%), and they often did not perform intention-to-treat analyses. Most studies had short follow-up (1–5 days), and only two studies<sup><xref ref-type="bibr" rid="bibr10-0269216311428528">10</xref>,<xref ref-type="bibr" rid="bibr24-0269216311428528">24</xref></sup> had longer observation periods (from 21 to 42 days). In four of them, there was evidence of sponsorship by industries.</p>
<table-wrap id="table4-0269216311428528" position="float">
<label>Table 4.</label>
<caption><p>Quality of the included studies.</p></caption>
<graphic alternate-form-of="table4-0269216311428528" xlink:href="10.1177_0269216311428528-table4.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Author/year</th>
<th align="left">Allocation concealment</th>
<th align="left">Large losses to follow-up (&gt; 20%)</th>
<th align="left">No intention to treat analysis</th>
<th align="left">Short follow-up (1–5 days)</th>
<th align="left">No sample size calculation</th>
<th align="left">Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duarte-Souza 2007</td>
<td>unclear</td>
<td/>
<td/>
<td>X</td>
<td>X</td>
<td/>
</tr>
<tr>
<td>Mercadante 2002</td>
<td>No</td>
<td/>
<td>X</td>
<td/>
<td>X</td>
<td/>
</tr>
<tr>
<td>Johnson 1994</td>
<td>Yes</td>
<td/>
<td/>
<td>X</td>
<td>X</td>
<td>sponsored</td>
</tr>
<tr>
<td>Bjorkman 1993</td>
<td>unclear</td>
<td/>
<td/>
<td>X</td>
<td>X</td>
<td/>
</tr>
<tr>
<td>Lomen 1986</td>
<td>unclear</td>
<td>X</td>
<td>X</td>
<td/>
<td>X</td>
<td>sponsored</td>
</tr>
<tr>
<td>Weingart 1985</td>
<td>Yes</td>
<td>X</td>
<td>X</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td>Ferrer Brechner 1984</td>
<td>unclear</td>
<td/>
<td/>
<td>X</td>
<td>X</td>
<td>sponsored</td>
</tr>
<tr>
<td>Israel 2010</td>
<td>Yes</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td/>
<td/>
</tr>
<tr>
<td>Cubero 2010</td>
<td>Yes</td>
<td/>
<td>X</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td>Tasmacioglu 2009</td>
<td>Yes</td>
<td/>
<td/>
<td>X</td>
<td>X</td>
<td/>
</tr>
<tr>
<td>Stockler 2004</td>
<td>Yes</td>
<td/>
<td>X</td>
<td>X</td>
<td/>
<td>sponsored</td>
</tr>
<tr>
<td>Axelsson 2003</td>
<td>unclear</td>
<td>X</td>
<td>X</td>
<td/>
<td>X</td>
<td/>
</tr>
</tbody>
</table>
</table-wrap>
<p>The differences in NSAIDs molecules employed, paracetamol dosages (3–5 g/day), and the different follow-up periods precluded the possibility to perform a meta-analysis of the studies presented.</p>
</sec>
</sec>
<sec id="sectiontion9-0269216311428528" sec-type="discussion">
<title>Discussion</title>
<p>The analgesic effect of paracetamol and NSAIDs in cancer pain has been demonstrated by placebo-controlled trials, as already summarized by two systematic reviews.<sup><xref ref-type="bibr" rid="bibr4-0269216311428528">4</xref>,<xref ref-type="bibr" rid="bibr26-0269216311428528">26</xref></sup> The role of these drugs in the management of cancer pain is based on their use at Step I and Step II of the WHO analgesic ladder, included in most of the available guidelines,<sup><xref ref-type="bibr" rid="bibr7-0269216311428528">7</xref></sup> and their use in this indication is beyond the scope of this review.</p>
<p>The addition of NSAIDs or paracetamol as part of Step III of the WHO ladder should be justified by the ability to improve opioid analgesia, by increasing pain relief offered by opioids alone, or by reducing opioid-related side effects in patients with poor pain relief and excessive side effects from opioid-alone analgesic regimens. The results of this systematic literature review, and of the previous Cochrane review,<sup><xref ref-type="bibr" rid="bibr4-0269216311428528">4</xref></sup> show that the available evidence cannot specifically answer this clinical question. In fact, three of the seven eligible studies<sup><xref ref-type="bibr" rid="bibr8-0269216311428528">8</xref>,<xref ref-type="bibr" rid="bibr22-0269216311428528">22</xref>,<xref ref-type="bibr" rid="bibr25-0269216311428528">25</xref></sup> showed an improvement in analgesia after the addition of one NSAIDs to Step III opioids, and two studies<sup><xref ref-type="bibr" rid="bibr10-0269216311428528">10</xref>,<xref ref-type="bibr" rid="bibr20-0269216311428528">20</xref></sup> showed a decrease in the opioid dose needed to obtain the same level of analgesia. Only one of five studies demonstrated a marginal analgesic advantage of combining paracetamol with morphine or hydromorphone.<sup><xref ref-type="bibr" rid="bibr14-0269216311428528">14</xref></sup> The paracetamol doses employed in the latter study (5 g/day) were higher than those usually considered safe in clinical practice.<sup><xref ref-type="bibr" rid="bibr27-0269216311428528">27</xref></sup> It is important to note that in some of the studies, baseline pain intensity was too low to permit the detection of clinically significant changes, probably meaning also that opioids were already giving significant pain relief in these patients.<sup><xref ref-type="bibr" rid="bibr10-0269216311428528">10</xref>,<xref ref-type="bibr" rid="bibr20-0269216311428528">20</xref>,<xref ref-type="bibr" rid="bibr22-0269216311428528">22</xref>,<xref ref-type="bibr" rid="bibr25-0269216311428528">25</xref></sup> The potential advantage of a reduction in the opioid dose needed to reach a similar degree of analgesia deserve additional studies to support a clinical practice indication.</p>
<p>All studies involved a relatively small number of patients (14 to 50) and had a short follow-up (1 to 14 days), with the exception of the only open parallel group study<sup><xref ref-type="bibr" rid="bibr10-0269216311428528">10</xref></sup> (study length from 21 to 39 days) and the study by Lomen<sup><xref ref-type="bibr" rid="bibr24-0269216311428528">24</xref></sup> (42 days duration). As none of the retrieved studies followed patients for a period of more than 12 weeks, it is difficult to generalize conclusions for the chronic use of these drugs.</p>
<p>The same is true considering the impact of side effects. The lack of intermediate to long-term follow-up makes it difficult to clearly address this issue. The study by Mercadante<sup><xref ref-type="bibr" rid="bibr10-0269216311428528">10</xref></sup> suggests potential relevance of specific NSAIDs gastrointestinal side effects, and it is evident that the general knowledge about the overall risk of gastrointestinal haemorrhage or perforation should be kept in mind also in this particular patient population.<sup><xref ref-type="bibr" rid="bibr28-0269216311428528">28</xref></sup> It is interesting to observe that at least in one study an increase in central nervous system side effects was seen with the addition of paracetamol to methadone, which questions the lack of sedating effects of NSAIDs/paracetamol as an absolute value of their role in combination treatment.</p>
<p>Due to the nature of the available data, it is impossible to decide whether the analgesic effect of NSAIDs is particularly helpful in different patient populations with cancer pain. The potential clinical advantage of the NSAIDs/opioid combination as suggested by clinical observations<sup><xref ref-type="bibr" rid="bibr29-0269216311428528">29</xref></sup> needs to be explored in specifically designed clinical trials. Also, the limited efficacy in time of NSAIDs or paracetamol administration for cancer pain, which was part of earlier clinical observations,<sup><xref ref-type="bibr" rid="bibr30-0269216311428528">30</xref></sup> should be better assessed by prospective controlled clinical trials.</p>
<p>The use of paracetamol in analgesics combination, also included at Step II of the WHO analgesic ladder and therefore in opioid-naïve patients, was based on a wide range of acute pharmacological studies on models of moderate pain,<sup><xref ref-type="bibr" rid="bibr31-0269216311428528">31</xref></sup> which demonstrated the additional analgesic effect of combining different dosages of codeine and paracetamol. The weak evidence, if any, of the effect of combining paracetamol with Step III opioids found in this review questions its role as a potential adjuvant to opioid analgesia in patients with more severe pain who are already on opioid treatment.</p>
</sec>
<sec id="sectiontion10-0269216311428528" sec-type="conclusions">
<title>Conclusion</title>
<p>With the highlighted limitations, there is weak evidence that NSAIDs can improve analgesia or reduce the opioid dose requirements for patients with cancer pain on a WHO Step III opioid regimen. The available evidence is too weak to support the use of paracetamol in this indication. The clinical practice implications of these results are limited by the lack of more direct evidence.</p>
</sec>
</body>
<back>
<sec id="sectiontion11-0269216311428528">
<title>Acknowledgement</title>
<p>The EPCRC has the overall aim to improve treatment of pain, depression and fatigue through translation research. Core scientific group/work package leaders: Stein Kaasa (project coordinator), Frank Skorpen, Marianne Jensen Hjermstad, and Jon Håvard Loge, Norwegian University of Science and Technology (NTNU); Geoffrey Hanks, University of Bristol; Augusto Caraceni and Franco De Conno, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Irene Higginson, King’s College London; Florian Strasser, Cantonal Hospital St Gallen; Lukas Radbruch, RWTH Aachen University; Kenneth Fearon, University of Edinburgh; Hellmut Samonigg, Medical University of Graz; Ketil Bø, Trollhetta AS, Norway; Irene Rech-Weichselbraun, Bender MedSystems GmbH, Austria; Odd Erik Gundersen, Verdande Technology AS, Norway. Scientific advisory group: Neil Aaronson, The Netherlands Cancer Institute; Vickie Baracos and Robin Fainsinger, University of Alberta; Patrick C. Stone, St. George’s University of London; Mari Lloyd-Williams, University of Liverpool. Project management: Stein Kaasa, Ola Dale, and Dagny F. Haugen, NTNU.</p>
</sec>
<sec id="sectiontion12-0269216311428528">
<title>Funding</title>
<p>This work was partially funded by the European Palliative Research Collaborative (EPCRC) through the European Union (EU) Sixth Framework Programme, contract no 037777, the Floriani Foundation of Milan, and the Italian Association for Cancer Research (AIRC) (grant IG 9347).</p>
</sec>
<sec id="sectiontion13-0269216311428528">
<title>Conflict of interest statement</title>
<p>None declared.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="bibr1-0269216311428528">
<label>1.</label>
<citation citation-type="book">
<collab>World Health Organization</collab>. <source>Cancer Pain Relief</source>, <comment>second edition, with a guide to opioid availability</comment>. <publisher-loc>Geneva</publisher-loc>: <publisher-name>WHO</publisher-name>, <year>1996</year>.</citation>
</ref>
<ref id="bibr2-0269216311428528">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Azevedo Sao Leao Ferreira</surname><given-names>K</given-names></name>
<name><surname>Kimura</surname><given-names>M</given-names></name>
<name><surname>Jacobsen Teixeira</surname><given-names>M</given-names></name>
</person-group>. <article-title>The WHO analgesic ladder for cancer pain control, twenty years of use. How much pain relief does one get from using it?</article-title> <source>Support Care Cancer</source> <year>2006</year>; <volume>14</volume>: <fpage>1086</fpage>–<lpage>1093</lpage>.</citation>
</ref>
<ref id="bibr3-0269216311428528">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vonkeman</surname><given-names>HE</given-names></name>
<name><surname>van</surname><given-names>de</given-names></name>
<name><surname>Laar</surname><given-names>MA</given-names></name>
</person-group>. <article-title>Nonsteroidal anti-inflammatory drugs: adverse effects and their prevention</article-title>. <source>Semin Arthritis Rheum</source> <year>2010</year>; <volume>39</volume>: <fpage>294</fpage>–<lpage>312</lpage>.</citation>
</ref>
<ref id="bibr4-0269216311428528">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McNicol</surname><given-names>E</given-names></name>
<name><surname>Strassels</surname><given-names>SA</given-names></name>
<name><surname>Goudas</surname><given-names>L</given-names></name>
<name><surname>Lau</surname><given-names>J</given-names></name>
<name><surname>Carr</surname><given-names>DB</given-names></name>
</person-group>. <article-title>NSAIDs or paracetamol, alone or combined with opioids, for cancer pain</article-title>. <source>Cochrane Database Syst Rev</source> <year>2005</year> <volume>25</volume>; (<issue>1</issue>):<fpage>CD005180</fpage>.</citation>
</ref>
<ref id="bibr5-0269216311428528">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hanks</surname><given-names>GW</given-names></name>
<name><surname>Conno</surname><given-names>F</given-names></name>
<name><surname>Cherny</surname><given-names>N</given-names></name>
<name><surname>Hanna</surname><given-names>M</given-names></name>
<name><surname>Kalso</surname><given-names>E</given-names></name>
<name><surname>McQuay</surname><given-names>HJ</given-names></name>
<etal/>
</person-group>. <article-title>Morphine and alternative opioids in cancer pain: the EAPC recommendations</article-title>. <source>Br J Cancer</source> <year>2001</year>; <volume>84</volume>: <fpage>587</fpage>–<lpage>593</lpage>.</citation>
</ref>
<ref id="bibr6-0269216311428528">
<label>6.</label>
<citation citation-type="web">
<collab>European Palliative Care Research Collaborative</collab>. <comment>Available at: <ext-link ext-link-type="uri" xlink:href="http://www.epcrc.org">www.epcrc.org</ext-link></comment>. (<access-date>accessed 31 March 2011</access-date>).</citation>
</ref>
<ref id="bibr7-0269216311428528">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pigni</surname><given-names>A</given-names></name>
<name><surname>Brunelli</surname><given-names>C</given-names></name>
<name><surname>Gibbins</surname><given-names>J</given-names></name>
<name><surname>Hanks</surname><given-names>G</given-names></name>
<name><surname>Deconno</surname><given-names>F</given-names></name>
<name><surname>Kaasa</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Content development for EUROPEAN GUIDELINES on the use of opioids for cancer pain: a systematic review and Expert Consensus Study</article-title>. <source>Minerva Anestesiol</source> <year>2010</year>; <volume>76</volume>: <fpage>833</fpage>–<lpage>843</lpage>.</citation>
</ref>
<ref id="bibr8-0269216311428528">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Duarte Souza</surname><given-names>JF</given-names></name>
<name><surname>Lajolo</surname><given-names>PP</given-names></name>
<name><surname>Pinczowski</surname><given-names>H</given-names></name>
<name><surname>del Giglio</surname><given-names>A</given-names></name>
</person-group>. <article-title>Adjunct dipyrone in association with oral morphine for cancer-related pain: the sooner the better</article-title>. <source>Support Care Cancer</source> <year>2007</year>; <volume>15</volume>: <fpage>1319</fpage>–<lpage>1323</lpage>.</citation>
</ref>
<ref id="bibr9-0269216311428528">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Xu</surname><given-names>JM</given-names></name>
<name><surname>Song</surname><given-names>ST</given-names></name>
<name><surname>Feng</surname><given-names>FY</given-names></name>
<name><surname>Huang</surname><given-names>FL</given-names></name>
<name><surname>Yang</surname><given-names>Y</given-names></name>
<name><surname>Xie</surname><given-names>GR</given-names></name>
<etal/>
</person-group>. <article-title>Cobrotoxin-containing analgesic compound to treat chronic moderate to severe cancer pain: results from a randomized, double-blind, cross-over study and from an open-label study</article-title>. <source>Oncol Rep</source> <year>2006</year>; <volume>16</volume>: <fpage>1077</fpage>–<lpage>1084</lpage>.</citation>
</ref>
<ref id="bibr10-0269216311428528">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mercadante</surname><given-names>S</given-names></name>
<name><surname>Fulfaro</surname><given-names>F</given-names></name>
<name><surname>Casuccio</surname><given-names>A</given-names></name>
</person-group>. <article-title>A randomised controlled study on the use of anti-inflammatory drugs in patients with cancer pain on morphine therapy: effects on dose-escalation and a pharmacoeconomic analysis</article-title>. <source>Eur J Cancer</source> <year>2002</year>; <volume>38</volume>: <fpage>1358</fpage>–<lpage>1363</lpage>.</citation>
</ref>
<ref id="bibr11-0269216311428528">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Israel</surname><given-names>FJ</given-names></name>
<name><surname>Parker</surname><given-names>G</given-names></name>
<name><surname>Charles</surname><given-names>M</given-names></name>
<name><surname>Reymond</surname><given-names>L</given-names></name>
</person-group>. <article-title>Lack of benefit from paracetamol (acetaminophen) for palliative cancer patients requiring high-dose strong opioids: a randomized, double-blind, placebo-controlled, crossover trial</article-title>. <source>J Pain Symptom Manage</source> <year>2010</year>; <volume>39</volume>: <fpage>548</fpage>–<lpage>554</lpage>.</citation>
</ref>
<ref id="bibr12-0269216311428528">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cubero</surname><given-names>DI</given-names></name>
<name><surname>del Giglio</surname><given-names>A</given-names></name>
</person-group>. <article-title>Early switching from morphine to methadone is not improved by acetaminophen in the analgesia of oncologic patients: a prospective, randomized, double-blind, placebo-controlled study</article-title>. <source>Support Care Cancer</source> <year>2010</year>; <volume>18</volume>: <fpage>235</fpage>–<lpage>242</lpage>.</citation>
</ref>
<ref id="bibr13-0269216311428528">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tasmacioglu</surname><given-names>B</given-names></name>
<name><surname>Aydinli</surname><given-names>I</given-names></name>
<name><surname>Keskinbora</surname><given-names>K</given-names></name>
<name><surname>Pekel</surname><given-names>AF</given-names></name>
<name><surname>Salihoglu</surname><given-names>T</given-names></name>
<name><surname>Sonsuz</surname><given-names>A</given-names></name>
</person-group>. <article-title>Effect of intravenous administration of paracetamol on morphine consumption in cancer pain control</article-title>. <source>Support Care Cancer</source> <year>2009</year>; <volume>17</volume>: <fpage>1475</fpage>–<lpage>1481</lpage>.</citation>
</ref>
<ref id="bibr14-0269216311428528">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stockler</surname><given-names>M</given-names></name>
<name><surname>Vardy</surname><given-names>J</given-names></name>
<name><surname>Pillai</surname><given-names>A</given-names></name>
<name><surname>Warr</surname><given-names>D</given-names></name>
</person-group>. <article-title>Acetaminophen (paracetamol) improves pain and well-being in people with advanced cancer already receiving a strong opioid regimen: a randomized, double-blind, placebo-controlled cross-over trial</article-title>. <source>J Clin Oncol</source> <year>2004</year>; <volume>22</volume>: <fpage>3389</fpage>–<lpage>3394</lpage>.</citation>
</ref>
<ref id="bibr15-0269216311428528">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Axelsson</surname><given-names>B</given-names></name>
<name><surname>Borup</surname><given-names>S</given-names></name>
</person-group>. <article-title>Is there an additive analgesic effect of paracetamol at step 3? A double-blind randomized controlled study</article-title>. <source>Palliat Med</source> <year>2003</year>; <volume>17</volume>: <fpage>724</fpage>–<lpage>725</lpage>.</citation>
</ref>
<ref id="bibr16-0269216311428528">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rodriguez</surname><given-names>RF</given-names></name>
<name><surname>Castillo</surname><given-names>JM</given-names></name>
<name><surname>Del Pilar Castillo</surname><given-names>M</given-names></name>
<name><surname>Nunez</surname><given-names>PD</given-names></name>
<name><surname>Rodriguez</surname><given-names>MF</given-names></name>
<name><surname>Restrepo</surname><given-names>JM</given-names></name>
<etal/>
</person-group>. <article-title>Codeine/acetaminophen and hydrocodone/acetaminophen combination tablets for the management of chronic cancer pain in adults: a 23-day, prospective, double-blind, randomized, parallel-group study</article-title>. <source>Clin Ther</source> <year>2007</year>; <volume>29</volume>: <fpage>581</fpage>–<lpage>587</lpage>.</citation>
</ref>
<ref id="bibr17-0269216311428528">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rodriguez</surname><given-names>RF</given-names></name>
<name><surname>Castillo</surname><given-names>JM</given-names></name>
<name><surname>Castillo</surname><given-names>MP</given-names></name>
<name><surname>Montoya</surname><given-names>O</given-names></name>
<name><surname>Daza</surname><given-names>P</given-names></name>
<name><surname>Rodriguez</surname><given-names>MF</given-names></name>
<etal/>
</person-group>. <article-title>Hydrocodone/acetaminophen and tramadol chlorhydrate combination tablets for the management of chronic cancer pain: a double-blind comparative trial</article-title>. <source>Clin J Pain</source> <year>2008</year>; <volume>24</volume>: <fpage>1</fpage>–<lpage>4</lpage>.</citation>
</ref>
<ref id="bibr18-0269216311428528">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mystakidou</surname><given-names>K</given-names></name>
<name><surname>Katsouda</surname><given-names>E</given-names></name>
<name><surname>Kouloulias</surname><given-names>V</given-names></name>
<name><surname>Kouvaris</surname><given-names>J</given-names></name>
<name><surname>Tsiatas</surname><given-names>M</given-names></name>
<name><surname>Vlahos</surname><given-names>L</given-names></name>
</person-group>. <article-title>Comparison of transdermal fentanyl with codeine/paracetamol, in combination with radiotherapy, for the management of metastatic bone pain</article-title>. <source>J Opioid Manage</source> <year>2005</year>; <volume>1</volume>: <fpage>204</fpage>–<lpage>210</lpage>.</citation>
</ref>
<ref id="bibr19-0269216311428528">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pistevou-Gompaki</surname><given-names>K</given-names></name>
<name><surname>Kouloulias</surname><given-names>VE</given-names></name>
<name><surname>Varveris</surname><given-names>C</given-names></name>
<name><surname>Mystakidou</surname><given-names>K</given-names></name>
<name><surname>Georgakopoulos</surname><given-names>G</given-names></name>
<name><surname>Eleftheriadis</surname><given-names>N</given-names></name>
<etal/>
</person-group>. <article-title>Radiotherapy plus either transdermal fentanyl or paracetamol and codeine for painful bone metastases: a randomised study of pain relief and quality of life</article-title>. <source>Curr Med Res Opin</source> <year>2004</year>; <volume>20</volume>: <fpage>159</fpage>–<lpage>163</lpage>.</citation>
</ref>
<ref id="bibr20-0269216311428528">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bjorkman</surname><given-names>R</given-names></name>
<name><surname>Ullman</surname><given-names>A</given-names></name>
<name><surname>Hedner</surname><given-names>J</given-names></name>
</person-group>. <article-title>Morphine-sparing effect of diclofenac in cancer pain</article-title>. <source>Eur J Clin Pharmacol</source> <year>1993</year>; <volume>44</volume>: <fpage>1</fpage>–<lpage>5</lpage>.</citation>
</ref>
<ref id="bibr21-0269216311428528">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chary</surname><given-names>S</given-names></name>
<name><surname>Goughnour</surname><given-names>BR</given-names></name>
<name><surname>Moulin</surname><given-names>DE</given-names></name>
<name><surname>Thorpe</surname><given-names>WR</given-names></name>
<name><surname>Harsanyi</surname><given-names>Z</given-names></name>
<name><surname>Darke</surname><given-names>AC</given-names></name>
</person-group>. <article-title>The dose–response relationship of controlled-release codeine (Codeine Contin) in chronic cancer pain</article-title>. <source>J Pain Symptom Manage</source> <year>1994</year>; <volume>9</volume>: <fpage>363</fpage>–<lpage>371</lpage>.</citation>
</ref>
<ref id="bibr22-0269216311428528">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ferrer-Brechner</surname><given-names>T</given-names></name>
<name><surname>Ganz</surname><given-names>P</given-names></name>
</person-group>. <article-title>Combination therapy with ibuprofen and methadone for chronic cancer pain</article-title>. <source>Am J Med</source> <year>1984</year>; <volume>77</volume>: <fpage>78</fpage>–<lpage>83</lpage>.</citation>
</ref>
<ref id="bibr23-0269216311428528">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Johnson</surname><given-names>JR</given-names></name>
<name><surname>Miller</surname><given-names>AJ</given-names></name>
</person-group>. <article-title>The efficacy of choline magnesium trisalicylate (CMT) in the management of metastatic bone pain: a pilot study</article-title>. <source>Palliat Med</source> <year>1994</year>; <volume>8</volume>: <fpage>129</fpage>–<lpage>135</lpage>.</citation>
</ref>
<ref id="bibr24-0269216311428528">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lomen</surname><given-names>PL</given-names></name>
<name><surname>Samal</surname><given-names>BA</given-names></name>
<name><surname>Lamborn</surname><given-names>KR</given-names></name>
<name><surname>Sattler</surname><given-names>LP</given-names></name>
<name><surname>Crampton</surname><given-names>SL</given-names></name>
</person-group>. <article-title>Flurbiprofen for the treatment of bone pain in patients with metastatic breast cancer</article-title>. <source>Am J Med</source> <year>1986</year>; <volume>24</volume>; <volume>80</volume>: <fpage>83</fpage>–<lpage>87</lpage>.</citation>
</ref>
<ref id="bibr25-0269216311428528">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Weingart</surname><given-names>WA</given-names></name>
<name><surname>Sorkness</surname><given-names>CA</given-names></name>
<name><surname>Earhart</surname><given-names>RH</given-names></name>
</person-group>. <article-title>Analgesia with oral narcotics and added ibuprofen in cancer patients</article-title>. <source>Clin Pharm</source> <year>1985</year>; <volume>4</volume>: <fpage>53</fpage>–<lpage>58</lpage>.</citation>
</ref>
<ref id="bibr26-0269216311428528">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eisenberg</surname><given-names>E</given-names></name>
<name><surname>Berkey</surname><given-names>CS</given-names></name>
<name><surname>Carr</surname><given-names>DB</given-names></name>
<name><surname>Mosteller</surname><given-names>F</given-names></name>
<name><surname>Chalmers</surname><given-names>TC</given-names></name>
</person-group>. <article-title>Efficacy and safety of nonsteroidal antiinflammatory drugs for cancer pain: a meta-analysis</article-title>. <source>J Clin Oncol</source> <year>1994</year>; <volume>12</volume>: <fpage>2756</fpage>–<lpage>2765</lpage>.</citation>
</ref>
<ref id="bibr27-0269216311428528">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Michna</surname><given-names>E</given-names></name>
<name><surname>Duh</surname><given-names>MS</given-names></name>
<name><surname>Korves</surname><given-names>C</given-names></name>
<name><surname>Dahl</surname><given-names>JL</given-names></name>
</person-group>. <article-title>Removal of opioid/acetaminophen combination prescription pain medications: assessing the evidence for hepatotoxicity and consequences of removal of these medications</article-title>. <source>Pain Med</source> <year>2010</year>; <volume>11</volume>: <fpage>369</fpage>–<lpage>378</lpage>.</citation>
</ref>
<ref id="bibr28-0269216311428528">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ng</surname><given-names>SC</given-names></name>
<name><surname>Chan</surname><given-names>FK</given-names></name>
</person-group>. <article-title>NSAIDS-induced gastrointestinal and cardiovascular injury</article-title>. <source>Curr Opin Gastroenterol</source> <year>2010</year>; <volume>26</volume>: <fpage>611</fpage>–<lpage>617</lpage>.</citation>
</ref>
<ref id="bibr29-0269216311428528">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Caraceni</surname><given-names>A</given-names></name>
<name><surname>Gorni</surname><given-names>G</given-names></name>
<name><surname>Zecca</surname><given-names>E</given-names></name>
<name><surname>De Conno</surname><given-names>F</given-names></name>
</person-group>. <article-title>More on the use of nonsteroidal anti-inflammatories in the management of cancer pain</article-title>. <source>J Pain Symptom Manage</source> <year>2001</year>; <volume>21</volume>: <fpage>89</fpage>–<lpage>91</lpage>.</citation>
</ref>
<ref id="bibr30-0269216311428528">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ventafridda</surname><given-names>V</given-names></name>
<name><surname>Tamburini</surname><given-names>M</given-names></name>
<name><surname>Caraceni</surname><given-names>A</given-names></name>
<name><surname>De Conno</surname><given-names>F</given-names></name>
<name><surname>Naldi</surname><given-names>F</given-names></name>
</person-group>. <article-title>A validation study of the WHO method for cancer pain relief</article-title>. <source>Cancer</source> <year>1987</year>; <volume>59</volume>: <fpage>850</fpage>–<lpage>856</lpage>.</citation>
</ref>
<ref id="bibr31-0269216311428528">
<label>31.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>McQuay</surname><given-names>HJ</given-names></name>
<name><surname>Moore</surname><given-names>A</given-names></name>
</person-group>. <source>An Evidence-Based Resource for Pain Relief</source>. <publisher-loc>Oxford</publisher-loc>: <publisher-name>Oxford University Press</publisher-name>, <year>1998</year>.</citation>
</ref>
</ref-list>
</back>
</article>